Search

everythinglearnresearchcommunity

for

Search:↓

PTHRP agonists can stimulate hair growth, especially in damaged follicles, while antagonists may initially increase growth but ultimately inhibit it.

Blocking the prolactin receptor might help treat various diseases, but more research is needed.

GLP-1 RAs may help wound healing but can also cause faster facial aging and skin issues.

20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.

GLP-1 receptor agonists may cause hair loss, but regrowth is rare.

GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.

GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.

Therapies targeting the androgen receptor are being developed to treat prostate cancer and improve bone and muscle health.

Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.

GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.

Inhibiting PDE8A may help treat hair loss by boosting fat cell growth and hair regeneration.

GLP-1 agonists may increase the risk of hair loss.

GLP-1 receptor agonists may help or harm hair health, needing more research.

GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.

Sinapic acid may help fight obesity and promote hair growth.

Thyroid receptor agonists may treat male pattern baldness without harmful side effects.

MR antagonists may improve skin health and wound healing, especially in aging.

Certain peptides can prevent hair loss in young rats caused by a cancer drug.

GLP-1RA therapy may increase the risk of hair loss.

New compounds were made that are promising for prostate cancer therapy.

Allopregnanolone may enhance alcohol's effects on dopamine neurons, influencing addiction risk.

Glucocorticoids reduce fat production in liver cells, while androgens increase it in females; manipulating certain enzymes can influence these effects.

Selective androgen receptor modulators (SARMs) are a promising type of drug for various health conditions due to their targeted actions.

Chronic GnRHa treatment can help manage endometrial hyperplasia and reduce ovarian androgen excess in PCO patients.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

A cream with a specific hormone blocker increases hair growth in mice.

GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.

Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.

Carbamates may help treat androgen-dependent conditions by changing how certain lipid enzymes are produced.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.